Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion [CNBC]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: CNBC
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T. In this article Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, regulatory and commercial milestones, it said. The transaction is expected to close in the second half of 2026. Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T. Current treatments require that work to be done outside the body, or ex vivo, a process that involves harvesting cells, engineering them in a lab and then reintroducing them. While logistically intensive, the procedure has been successful for blood cancers like multiple myeloma. “It's an intravenously delivered therapy, one time,” said Jacob Van Naarden, president of Lill
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion [MSNBC.com]MSNBC.com
- Johnson & Johnson (JNJ) had its price target raised by Guggenheim from $244.00 to $266.00. They now have a "buy" rating on the stock.MarketBeat
- Is ALPS (OUSA) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- The Smartest Dividend Stocks to Buy With $2,000 Right Now [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Could This Healthcare Stock Help Make You Rich Over the Next Decade? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website